豪江智能(301320.SZ):目前公司在醫養領域重點市場仍然主要集中在國外
格隆匯1月24日丨豪江智能(301320.SZ)於2024年1月24日接受特定對象調研,就“目前國內智能護理牀的市場滲透率還是比較低,公司有做這方面的打算嗎?”,公司回覆稱,目前公司在醫養領域重點市場仍然主要集中在國外,未來將繼續以智能線性驅動產品的生產、銷售、研發為核心業務,以提升公司產品的科技含量、不斷開拓新的業務領域和應用場景,持續深耕智能線性驅動市場為發展戰略。公司堅持以產品為中心的創新發展之路,以市場和客户需求為導向,立足中國,面向全球,逐步鞏固並提升產品科技含量和國內外市場佔有率,着力打造具有國內品牌優勢和國際影響力的智能線性驅動行業龍頭企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.